What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
复制标题
DOI：
10.1136/bjophthalmol-2013-303844
复制
发表时间：
2014-06-01
影响因子：
4.1
通讯作者：
Avery, Robert L.
中科院分区：
文献类型：
--
作者：
Avery, Robert L.
抗血管内皮生长因子（VEGF）治疗已经彻底改变了视网膜疾病的治疗，并且似乎非常安全。然而，有几条证据表明，小剂量的这些药物可能会产生全身性影响。这些全身效应的临床意义尚不清楚，但需要进一步研究。
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.